相关实验视频

Updated: May 6, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

按摩疗法对多发性硬化症患者的影响,系统性审查

Ioannis Giannou¹, Margarita Katsina¹, Zacharias Dimitriadis²

¹Department of Physiotherapy, Human Performance & Rehabilitation Laboratory, School of Health Sciences, University of Thessaly, 3rd km Old National Road Lamia, Lamia, 35100 Athens, Greece.

Multiple sclerosis and related disorders

|March 15, 2025

概括

催眠疗法对多发性硬化症 (MS) 症状如平衡和疲劳产生了积极的影响. 需要更多的研究来证实MS患者治疗骑马的好处.

科学领域:

神经科学是一个神经科学.
康复医学康复医学康复医学
动物辅助疗法是一种动物辅助疗法.

背景情况:

多发性硬化症 (MS) 是一种进展性神经退行性疾病,严重影响患者的日常生活.
目前的治疗方法旨在控制多发性硬化症的症状,但正在探索创新的干预措施.
使用马匹进行治疗的治疗干预方法河马疗法在各种神经疾病中表现有前途.

研究的目的:

对多发性硬化症 (MS) 患者的催眠疗法的影响进行系统审查现有研究.
评估hippotherapy作为MS患者干预措施的可衡量的益处.
评估河床治疗对MS患者的临床画面和功能状态的影响.

主要方法:

通过使用PubMed,Scopus,Cochrane图书馆和EBSCO等数据库进行了对研究的系统审查.
关键词包括"多发性硬化症"",多发性硬化症"",马术治疗"和"马疗法".
选择了五项随机对照试验,并使用PEDro规模对其质量进行了评估.

主要成果:

对5项随机对照试验的分析揭示了海马疗法对多种多发性硬化症症状的积极影响.
观察到的好处包括平衡,疲劳,,疼痛和生活质量的改善.
催眠疗法还对MS患者的肌肉力量,行走能力和耐力产生了积极的影响.

结论:

催眠疗法显示出作为改善多发性硬化症症状的有效干预措施的潜力.
在平衡,疲劳,步态,性,疼痛,肌肉力量和生活质量方面注意到了积极的影响.
建议进行进一步的高质量研究,以加强MS治疗中海马治疗的证据基础.

关键词:

催眠疗法 (Hippotherapy) 是一种治疗方法.多发性硬化症是多发性硬化症.系统性审查系统性审查治疗性骑行是一种疗法.

更多相关视频

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Published on: January 29, 2016

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

相关概念视频

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...